secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001171843-24-000164
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics appoints Bisker-Leib as CEO, Schuetz to President of R&D
-----------------------------------------------------------------------------

- Vered Bisker-Leib appointed CEO effective Jan 9, 2024; salary increased to $600k, target bonus 55%.
- Thomas Schuetz transitions from CEO to President of R&D and Vice Chair of Board.
- Bisker-Leib receives options for 1,753,125 shares and RSUs for 1,753,125 shares at $1.93 exercise price.
- Schuetz receives options for 637,500 shares and RSUs for 637,500 shares at $1.93.
- Preliminary unaudited cash, equivalents and marketable securities approx $152M as of Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/f8k_010924.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-000164

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer